CN114053259A - 包含麝香草酚三甲氧基肉桂酸酯的皮肤瘙痒或刺激缓解用组合物 - Google Patents
包含麝香草酚三甲氧基肉桂酸酯的皮肤瘙痒或刺激缓解用组合物 Download PDFInfo
- Publication number
- CN114053259A CN114053259A CN202110884099.6A CN202110884099A CN114053259A CN 114053259 A CN114053259 A CN 114053259A CN 202110884099 A CN202110884099 A CN 202110884099A CN 114053259 A CN114053259 A CN 114053259A
- Authority
- CN
- China
- Prior art keywords
- composition
- day
- thymol
- weight
- skin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 86
- 208000003251 Pruritus Diseases 0.000 title claims abstract description 60
- GTPUEIXKLQUDEJ-CSKARUKUSA-N (5-methyl-2-propan-2-ylphenyl) (e)-3-(3,4,5-trimethoxyphenyl)prop-2-enoate Chemical compound COC1=C(OC)C(OC)=CC(\C=C\C(=O)OC=2C(=CC=C(C)C=2)C(C)C)=C1 GTPUEIXKLQUDEJ-CSKARUKUSA-N 0.000 title claims abstract description 50
- 230000007803 itching Effects 0.000 title abstract description 19
- 230000007794 irritation Effects 0.000 title abstract description 12
- 150000003839 salts Chemical class 0.000 claims abstract description 37
- 239000012453 solvate Substances 0.000 claims abstract description 26
- 108010053752 Voltage-Gated Sodium Channels Proteins 0.000 claims abstract description 19
- 102000016913 Voltage-Gated Sodium Channels Human genes 0.000 claims abstract description 19
- 206010040880 Skin irritation Diseases 0.000 claims abstract description 16
- 231100000475 skin irritation Toxicity 0.000 claims abstract description 16
- 230000036556 skin irritation Effects 0.000 claims abstract description 16
- 239000000126 substance Substances 0.000 claims description 17
- 238000002360 preparation method Methods 0.000 claims description 11
- 239000002537 cosmetic Substances 0.000 claims description 10
- 235000013305 food Nutrition 0.000 claims description 9
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- 230000000694 effects Effects 0.000 abstract description 15
- 239000004615 ingredient Substances 0.000 abstract description 8
- 238000000034 method Methods 0.000 abstract description 7
- 210000003491 skin Anatomy 0.000 description 24
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 20
- 210000004027 cell Anatomy 0.000 description 14
- 238000009472 formulation Methods 0.000 description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 11
- 150000001875 compounds Chemical class 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- FVECELJHCSPHKY-WTFKENEKSA-N Veratrine (amorphous) Chemical compound C1=C(OC)C(OC)=CC=C1C(=O)O[C@@H]1[C@]2(O)O[C@@]34C[C@@]5(O)[C@H](CN6[C@@H](CC[C@H](C)C6)[C@@]6(C)O)[C@]6(O)[C@@H](O)C[C@@]5(O)[C@@H]4CC[C@H]2[C@]3(C)CC1 FVECELJHCSPHKY-WTFKENEKSA-N 0.000 description 10
- 238000007796 conventional method Methods 0.000 description 10
- 239000002552 dosage form Substances 0.000 description 10
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
- 239000006071 cream Substances 0.000 description 9
- 239000008213 purified water Substances 0.000 description 9
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 8
- FVECELJHCSPHKY-UHFFFAOYSA-N Veratridine Natural products C1=C(OC)C(OC)=CC=C1C(=O)OC1C2(O)OC34CC5(O)C(CN6C(CCC(C)C6)C6(C)O)C6(O)C(O)CC5(O)C4CCC2C3(C)CC1 FVECELJHCSPHKY-UHFFFAOYSA-N 0.000 description 8
- 239000000839 emulsion Substances 0.000 description 8
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 7
- 102000018674 Sodium Channels Human genes 0.000 description 7
- 108010052164 Sodium Channels Proteins 0.000 description 7
- 235000011187 glycerol Nutrition 0.000 description 7
- 229960004194 lidocaine Drugs 0.000 description 7
- 239000002304 perfume Substances 0.000 description 7
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- 101000654386 Homo sapiens Sodium channel protein type 9 subunit alpha Proteins 0.000 description 6
- 230000002421 anti-septic effect Effects 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 238000011156 evaluation Methods 0.000 description 6
- 239000000499 gel Substances 0.000 description 6
- 239000000049 pigment Substances 0.000 description 6
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 6
- 239000008187 granular material Substances 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- WWZKQHOCKIZLMA-UHFFFAOYSA-N Caprylic acid Natural products CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 4
- 229920002125 Sokalan® Polymers 0.000 description 4
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 4
- CDQSJQSWAWPGKG-UHFFFAOYSA-N butane-1,1-diol Chemical compound CCCC(O)O CDQSJQSWAWPGKG-UHFFFAOYSA-N 0.000 description 4
- GHBFNMLVSPCDGN-UHFFFAOYSA-N caprylic acid monoglyceride Natural products CCCCCCCC(=O)OCC(O)CO GHBFNMLVSPCDGN-UHFFFAOYSA-N 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 230000001419 dependent effect Effects 0.000 description 4
- BRZYSWJRSDMWLG-CAXSIQPQSA-N geneticin Chemical compound O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](C(C)O)O2)N)[C@@H](N)C[C@H]1N BRZYSWJRSDMWLG-CAXSIQPQSA-N 0.000 description 4
- 229960001340 histamine Drugs 0.000 description 4
- 239000006210 lotion Substances 0.000 description 4
- 210000005036 nerve Anatomy 0.000 description 4
- 239000011535 reaction buffer Substances 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 3
- 239000012981 Hank's balanced salt solution Substances 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- 235000013361 beverage Nutrition 0.000 description 3
- 229960001631 carbomer Drugs 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 235000019634 flavors Nutrition 0.000 description 3
- 150000004677 hydrates Chemical class 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 229940057995 liquid paraffin Drugs 0.000 description 3
- 239000003589 local anesthetic agent Substances 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 239000002674 ointment Substances 0.000 description 3
- 229920000151 polyglycol Polymers 0.000 description 3
- 239000010695 polyglycol Substances 0.000 description 3
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 3
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 3
- 229940068968 polysorbate 80 Drugs 0.000 description 3
- 229920000053 polysorbate 80 Polymers 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 229960001896 pramocaine Drugs 0.000 description 3
- DQKXQSGTHWVTAD-UHFFFAOYSA-N pramocaine Chemical compound C1=CC(OCCCC)=CC=C1OCCCN1CCOCC1 DQKXQSGTHWVTAD-UHFFFAOYSA-N 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 230000002335 preservative effect Effects 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 239000002453 shampoo Substances 0.000 description 3
- 239000007901 soft capsule Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 229940032094 squalane Drugs 0.000 description 3
- LADGBHLMCUINGV-UHFFFAOYSA-N tricaprin Chemical compound CCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCC)COC(=O)CCCCCCCCC LADGBHLMCUINGV-UHFFFAOYSA-N 0.000 description 3
- 235000013343 vitamin Nutrition 0.000 description 3
- 239000011782 vitamin Substances 0.000 description 3
- 229940088594 vitamin Drugs 0.000 description 3
- 229930003231 vitamin Natural products 0.000 description 3
- CUNWUEBNSZSNRX-RKGWDQTMSA-N (2r,3r,4r,5s)-hexane-1,2,3,4,5,6-hexol;(z)-octadec-9-enoic acid Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O CUNWUEBNSZSNRX-RKGWDQTMSA-N 0.000 description 2
- LEACJMVNYZDSKR-UHFFFAOYSA-N 2-octyldodecan-1-ol Chemical compound CCCCCCCCCCC(CO)CCCCCCCC LEACJMVNYZDSKR-UHFFFAOYSA-N 0.000 description 2
- ANZUDYZHSVGBRF-UHFFFAOYSA-N 3-ethylnonane-1,2,3-triol Chemical compound CCCCCCC(O)(CC)C(O)CO ANZUDYZHSVGBRF-UHFFFAOYSA-N 0.000 description 2
- XMIIGOLPHOKFCH-UHFFFAOYSA-N 3-phenylpropionic acid Chemical compound OC(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-N 0.000 description 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 2
- 108091006146 Channels Proteins 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- 208000010201 Exanthema Diseases 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 206010064571 Gene mutation Diseases 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 102000004310 Ion Channels Human genes 0.000 description 2
- 108090000862 Ion Channels Proteins 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 229920001214 Polysorbate 60 Polymers 0.000 description 2
- 239000004372 Polyvinyl alcohol Substances 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
- 102100031367 Sodium channel protein type 9 subunit alpha Human genes 0.000 description 2
- HFJHNGKIVAKCIW-UHFFFAOYSA-N Stearyl monoglyceridyl citrate Chemical compound OCC(O)CO.OC(=O)CC(O)(CC(O)=O)CC(O)=O.CCCCCCCCCCCCCCCCCC(O)=O HFJHNGKIVAKCIW-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 241000489523 Veratrum Species 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 229930013930 alkaloid Natural products 0.000 description 2
- 150000003797 alkaloid derivatives Chemical class 0.000 description 2
- 229960000458 allantoin Drugs 0.000 description 2
- 230000001139 anti-pruritic effect Effects 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- BTFJIXJJCSYFAL-UHFFFAOYSA-N arachidyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCO BTFJIXJJCSYFAL-UHFFFAOYSA-N 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- YKPUWZUDDOIDPM-SOFGYWHQSA-N capsaicin Chemical compound COC1=CC(CNC(=O)CCCC\C=C\C(C)C)=CC=C1O YKPUWZUDDOIDPM-SOFGYWHQSA-N 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 239000004359 castor oil Substances 0.000 description 2
- 235000019438 castor oil Nutrition 0.000 description 2
- 229940082500 cetostearyl alcohol Drugs 0.000 description 2
- UWGBIKPRXRSRNM-UHFFFAOYSA-N cevadine Natural products CC=C(C)/C(=O)OC1CCC2(C)C3CCC4C5(O)CC(O)C6(O)C(CN7CC(C)CCC7C6(C)O)C5(O)CC24OCC13O UWGBIKPRXRSRNM-UHFFFAOYSA-N 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 235000015165 citric acid Nutrition 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- DLAHAXOYRFRPFQ-UHFFFAOYSA-N dodecyl benzoate Chemical compound CCCCCCCCCCCCOC(=O)C1=CC=CC=C1 DLAHAXOYRFRPFQ-UHFFFAOYSA-N 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 201000005884 exanthem Diseases 0.000 description 2
- 239000006260 foam Substances 0.000 description 2
- 235000015203 fruit juice Nutrition 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 2
- UBHWBODXJBSFLH-UHFFFAOYSA-N hexadecan-1-ol;octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO.CCCCCCCCCCCCCCCCCCO UBHWBODXJBSFLH-UHFFFAOYSA-N 0.000 description 2
- ACCCMOQWYVYDOT-UHFFFAOYSA-N hexane-1,1-diol Chemical compound CCCCCC(O)O ACCCMOQWYVYDOT-UHFFFAOYSA-N 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 229960005015 local anesthetics Drugs 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- TXXHDPDFNKHHGW-UHFFFAOYSA-N muconic acid Chemical compound OC(=O)C=CC=CC(O)=O TXXHDPDFNKHHGW-UHFFFAOYSA-N 0.000 description 2
- 231100000957 no side effect Toxicity 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 239000003002 pH adjusting agent Substances 0.000 description 2
- 230000001314 paroxysmal effect Effects 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 2
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 2
- 229940113124 polysorbate 60 Drugs 0.000 description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 description 2
- 229960001807 prilocaine Drugs 0.000 description 2
- MVFGUOIZUNYYSO-UHFFFAOYSA-N prilocaine Chemical compound CCCNC(C)C(=O)NC1=CC=CC=C1C MVFGUOIZUNYYSO-UHFFFAOYSA-N 0.000 description 2
- 230000000770 proinflammatory effect Effects 0.000 description 2
- 206010037844 rash Diseases 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 208000017520 skin disease Diseases 0.000 description 2
- 231100000046 skin rash Toxicity 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- 239000003195 sodium channel blocking agent Substances 0.000 description 2
- 229960005078 sorbitan sesquioleate Drugs 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 229960000281 trometamol Drugs 0.000 description 2
- PSVXZQVXSXSQRO-UHFFFAOYSA-N undecaethylene glycol Chemical compound OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO PSVXZQVXSXSQRO-UHFFFAOYSA-N 0.000 description 2
- 235000013311 vegetables Nutrition 0.000 description 2
- 229940057613 veratrum Drugs 0.000 description 2
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 1
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- ADMRVOGGYMFGCZ-VCHYOVAHSA-N (E)-2-(5-methyl-2-propan-2-ylphenyl)-3-(3,4,5-trimethoxyphenyl)prop-2-enoic acid Chemical group CC=1C=CC(=C(C=1)/C(/C(=O)O)=C\C1=CC(=C(C(=C1)OC)OC)OC)C(C)C ADMRVOGGYMFGCZ-VCHYOVAHSA-N 0.000 description 1
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 description 1
- MIOPJNTWMNEORI-GMSGAONNSA-N (S)-camphorsulfonic acid Chemical compound C1C[C@@]2(CS(O)(=O)=O)C(=O)C[C@@H]1C2(C)C MIOPJNTWMNEORI-GMSGAONNSA-N 0.000 description 1
- WHTVZRBIWZFKQO-AWEZNQCLSA-N (S)-chloroquine Chemical compound ClC1=CC=C2C(N[C@@H](C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-AWEZNQCLSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- AMMPLVWPWSYRDR-UHFFFAOYSA-N 1-methylbicyclo[2.2.2]oct-2-ene-4-carboxylic acid Chemical compound C1CC2(C(O)=O)CCC1(C)C=C2 AMMPLVWPWSYRDR-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- UPHOPMSGKZNELG-UHFFFAOYSA-N 2-hydroxynaphthalene-1-carboxylic acid Chemical compound C1=CC=C2C(C(=O)O)=C(O)C=CC2=C1 UPHOPMSGKZNELG-UHFFFAOYSA-N 0.000 description 1
- MLMQPDHYNJCQAO-UHFFFAOYSA-N 3,3-dimethylbutyric acid Chemical compound CC(C)(C)CC(O)=O MLMQPDHYNJCQAO-UHFFFAOYSA-N 0.000 description 1
- MIDXCONKKJTLDX-UHFFFAOYSA-N 3,5-dimethylcyclopentane-1,2-dione Chemical compound CC1CC(C)C(=O)C1=O MIDXCONKKJTLDX-UHFFFAOYSA-N 0.000 description 1
- XLZYKTYMLBOINK-UHFFFAOYSA-N 3-(4-hydroxybenzoyl)benzoic acid Chemical compound OC(=O)C1=CC=CC(C(=O)C=2C=CC(O)=CC=2)=C1 XLZYKTYMLBOINK-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- ZRPLANDPDWYOMZ-UHFFFAOYSA-N 3-cyclopentylpropionic acid Chemical compound OC(=O)CCC1CCCC1 ZRPLANDPDWYOMZ-UHFFFAOYSA-N 0.000 description 1
- RJWBTWIBUIGANW-UHFFFAOYSA-N 4-chlorobenzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=C(Cl)C=C1 RJWBTWIBUIGANW-UHFFFAOYSA-N 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 241001474374 Blennius Species 0.000 description 1
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- TXXHDPDFNKHHGW-CCAGOZQPSA-N Muconic acid Natural products OC(=O)\C=C/C=C\C(O)=O TXXHDPDFNKHHGW-CCAGOZQPSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 108090000189 Neuropeptides Proteins 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 235000019482 Palm oil Nutrition 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 102000003610 TRPM8 Human genes 0.000 description 1
- 102000003566 TRPV1 Human genes 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 101150111302 Trpm8 gene Proteins 0.000 description 1
- 101150016206 Trpv1 gene Proteins 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000001166 anti-perspirative effect Effects 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 239000003213 antiperspirant Substances 0.000 description 1
- 239000003908 antipruritic agent Substances 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- GONOPSZTUGRENK-UHFFFAOYSA-N benzyl(trichloro)silane Chemical compound Cl[Si](Cl)(Cl)CC1=CC=CC=C1 GONOPSZTUGRENK-UHFFFAOYSA-N 0.000 description 1
- 239000003613 bile acid Substances 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 239000012888 bovine serum Substances 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 239000008338 calamine lotion Substances 0.000 description 1
- 229940046731 calcineurin inhibitors Drugs 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 229960002504 capsaicin Drugs 0.000 description 1
- 235000017663 capsaicin Nutrition 0.000 description 1
- 235000013736 caramel Nutrition 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 229960003677 chloroquine Drugs 0.000 description 1
- WHTVZRBIWZFKQO-UHFFFAOYSA-N chloroquine Natural products ClC1=CC=C2C(NC(C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-UHFFFAOYSA-N 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 230000037336 dry skin Effects 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- AFAXGSQYZLGZPG-UHFFFAOYSA-N ethanedisulfonic acid Chemical compound OS(=O)(=O)CCS(O)(=O)=O AFAXGSQYZLGZPG-UHFFFAOYSA-N 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 238000005187 foaming Methods 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 239000013538 functional additive Substances 0.000 description 1
- 235000021255 galacto-oligosaccharides Nutrition 0.000 description 1
- 150000003271 galactooligosaccharides Chemical class 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- 150000008131 glucosides Chemical class 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 239000000118 hair dye Substances 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 230000000887 hydrating effect Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 239000001023 inorganic pigment Substances 0.000 description 1
- 230000000622 irritating effect Effects 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 229940041616 menthol Drugs 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N n-hexanoic acid Natural products CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-N naphthalene-2-sulfonic acid Chemical compound C1=CC=CC2=CC(S(=O)(=O)O)=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-N 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 239000003605 opacifier Substances 0.000 description 1
- 229940005483 opioid analgesics Drugs 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000012860 organic pigment Substances 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 239000002540 palm oil Substances 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- -1 patch Substances 0.000 description 1
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 210000000578 peripheral nerve Anatomy 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- IUGYQRQAERSCNH-UHFFFAOYSA-N pivalic acid Chemical compound CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229950008882 polysorbate Drugs 0.000 description 1
- WSHYKIAQCMIPTB-UHFFFAOYSA-M potassium;2-oxo-3-(3-oxo-1-phenylbutyl)chromen-4-olate Chemical compound [K+].[O-]C=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 WSHYKIAQCMIPTB-UHFFFAOYSA-M 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 229940107700 pyruvic acid Drugs 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 230000037307 sensitive skin Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229910001415 sodium ion Inorganic materials 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 229950011392 sorbitan stearate Drugs 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 150000003408 sphingolipids Chemical class 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 239000006097 ultraviolet radiation absorber Substances 0.000 description 1
- 230000008728 vascular permeability Effects 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- CPYIZQLXMGRKSW-UHFFFAOYSA-N zinc;iron(3+);oxygen(2-) Chemical compound [O-2].[O-2].[O-2].[O-2].[Fe+3].[Fe+3].[Zn+2] CPYIZQLXMGRKSW-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/52—Adding ingredients
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/37—Esters of carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/005—Preparations for sensitive skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q5/00—Preparations for care of the hair
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/318—Foods, ingredients or supplements having a functional effect on health having an effect on skin health and hair or coat
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/30—Other Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/74—Biological properties of particular ingredients
- A61K2800/75—Anti-irritant
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Dermatology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Birds (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Mycology (AREA)
- Toxicology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Cosmetics (AREA)
Abstract
一种包含麝香草酚三甲氧基肉桂酸酯的皮肤瘙痒或刺激缓解用组合物。本说明书公开了包含麝香草酚三甲氧基肉桂酸酯、其立体异构体、盐、水合物或溶剂合物作为有效成分的皮肤瘙痒或刺激缓解用组合物以及通过将所述组合物投入到需要缓解皮肤瘙痒或刺激的个体中来缓解皮肤瘙痒或皮肤刺激的方法。通过本说明书公开的组合物无副作用的同时,抑制电压门控钠通道NaV1.7(voltage‑gated sodium channel Nav1.7),从而缓解皮肤瘙痒或皮肤刺激的效果优异。
Description
技术领域
本公开涉及一种缓解皮肤瘙痒或刺激的组合物。
背景技术
瘙痒作为皮肤疾病的主要症状,可以说是诱导想要抓挠的心的感觉,是对有害刺激的回避反应,除了皮肤疾病之外,也可能因全身疾病或精神疾病而引发。
中枢和末梢的介质均对瘙痒症起到重要的作用,促炎性(pro-inflammatory)介质在皮疹之类炎症性皮肤疾病中诱发瘙痒症,这些介质的大部分可能引发炎症的其他先兆,即疼痛、血管扩张导致的红斑、血管渗透性增加等。另外,通过由与组胺不同的肥大细胞(Mast cell)分泌的因子或前列腺素的活动增加而可能诱发瘙痒。此外,也可以由胆汁酸、蛋白分解酶、细胞因子、神经肽和氯喹、类鸦片之类化合物通过分布在末梢神经的各受体传达瘙痒信号。虽然针对这些各种目标使用了抗瘙痒剂,但是药物存在局限性,局部的炉甘石洗液的瘙痒缓解功效弱,类固醇虽然减少炎症而缓解瘙痒,但长期使用困难。据悉,在钙调磷酸酶抑制剂的情况下,会暂时诱发疼痛,并增加恶性肿瘤的危险性。薄荷醇、辣椒素洗液可以使分布在各神经的离子通道(TRPM8、TRPV1等)激活并起作用而有助于缓解瘙痒,但存在刺激很大的缺点。抗组胺剂对由组胺引发的皮疹之类瘙痒症有局限性。(变态反应和临床免疫学杂志2018;142:1375-90瘙痒的病因及(新型)治疗方法。)
另一方面,利多卡因(lidocaine)、普莫卡因(pramoxine)、丙胺卡因(prilocaine)等局部麻醉剂类也减少了传达神经信号的神经膜的钠离子通过,防止刺激、瘙痒信号传达,从而用于瘙痒缓解以及疼痛缓解。
如此,在感知刺激的主要末梢组织即皮肤和皮肤神经中分布着各种刺激、疼痛以及瘙痒诱发介质的受体,这种受体所接收的各个刺激从神经系统以电信号形式传达到中枢神经系统,起到这种作用的离子通道被认为是电压门控钠通道(voltage-gated sonachannel)。尤其,最近在论文中报告了所述电压门控钠通道与瘙痒的关联性。(Cell 157,1393–1404,June 5,2014,一种用于缓解疼痛和瘙痒的Nav1.7通道电压传感器的单克隆抗体;PAIN 155(2014)1702–1707,Nav1.7基因突变引起的阵发性瘙痒;国际分子科学杂志,2019,20,6058,3'-O-甲基异丁醇抑制电压门控钠通道Nav1.7对组胺依赖性瘙痒小鼠模型中的止痒作用)。另外,用作瘙痒缓解剂的局部麻醉剂利多卡因、普莫卡因等是传统的非选择性钠通道阻滞剂(sodium channel blocker)。
(非专利文献1)变态反应临床免疫学杂志2018;142:1375-90,瘙痒的病因及(新型)治疗方法。
(非专利文献2)Cell 157,1393–1404,June 5,2014,一种用于缓解疼痛和瘙痒的NaV1.7通道电压传感器的单克隆抗体。
(非专利文献2)PAIN 155(2014)1702–1707,Nav1.7基因突变引起的阵发性瘙痒。
(非专利文献2)国际分子科学杂志2019,20,6058,3′-O-甲基异丁醇抑制电压门控钠通道Nav1.7对组胺依赖性瘙痒小鼠模型中的止痒作用。
发明内容
在一方面,本公开的目的在于提供一种皮肤瘙痒或皮肤刺激缓解效果优异的组合物。
在一方面,本公开的目的在于提供一种用于制备皮肤瘙痒或皮肤刺激缓解用组合物的麝香草酚三甲氧基肉桂酸酯、其立体异构体、盐、水合物或溶剂合物的用途。
在一方面,本公开提供一种用于制备皮肤瘙痒或皮肤刺激缓解用组合物的麝香草酚三甲氧基肉桂酸酯、其立体异构体、盐、水合物或溶剂合物的用途。
在例示性的一实现例中,可以是,所述麝香草酚三甲氧基肉桂酸酯由下述化学式1表示。
[化学式1]
在例示性的一实现例中,可以是,所述麝香草酚三甲氧基肉桂酸酯、其立体异构体、盐、水合物或溶剂合物的给药量为0.37至37mg/kg/日。
在例示性的一实现例中,可以是,所述组合物抑制电压门控钠通道NaV1.7(voltage-gated sodium channel Nav1.7)。
在例示性的一实现例中,可以是,所述皮肤瘙痒或皮肤刺激是由化学物质引起的。
在例示性的一实现例中,所述化学物质可以是藜芦碱(veratrum alkaloid),所述藜芦碱可以是藜芦定(veratridine)。
在例示性的一实现例中,可以是,所述组合物为皮肤外用剂组合物。
在例示性的一实现例中,可以是,所述组合物为食品、化妆料或药学组合物。
在一方面,根据本公开的包含麝香草酚三甲氧基肉桂酸酯、其立体异构体、盐、水合物或溶剂合物的组合物无副作用的同时皮肤瘙痒缓解效果显著。
在另一方面,根据本公开的包含麝香草酚三甲氧基肉桂酸酯、其立体异构体、盐、水合物或溶剂合物的组合物无副作用的同时皮肤刺激缓解效果显著。
在另一方面,根据本公开的包含麝香草酚三甲氧基肉桂酸酯、其立体异构体、盐、水合物或溶剂合物的组合物能够抑制电压门控钠通道NaV1.7(voltage-gated sodiumchannel Nav1.7)。
附图说明
图1是示出基于麝香草酚三甲氧基肉桂酸酯处理的电压门控钠通道NaV1.7(voltage-gated sodium channel Nav1.7)抑制率的图表。
图2是示出基于麝香草酚三甲氧基肉桂酸酯处理的瘙痒缓解效果的图表(对应标本t-黑色**p<0.1,***p<0.01)。
具体实施方式
以下,详细说明本公开。
在一方面,本公开提供一种包含麝香草酚三甲氧基肉桂酸酯、其立体异构体、盐、水合物或溶剂合物的皮肤瘙痒或刺激缓解用组合物。
在一方面,本公开提供一种用于制备皮肤瘙痒或皮肤刺激缓解用组合物的麝香草酚三甲氧基肉桂酸酯、其立体异构体、盐、水合物或溶剂合物的用途。
在一实现例中,所述麝香草酚三甲氧基肉桂酸酯为由下述化学式1表示的(5-甲基-2-丙烷-2-基苯基)(E)-3-(3,4,5-三甲氧基苯基)丙-2-烯酸。
[化学式1]
在本说明书中,“立体异构体”包含光学异构体(optical isomers),例如,本质上纯的对映异构体(essentially pure enantiomers),本质上纯的非对映异构体(essentially pure diastereomers)或它们的混合物。
在本说明书中,“本质上纯(essentially pure)”意指,例如当与对映异构体或非对映异构体关联使用时,可以以对映异构体或非对映异构体为例的具体化合物存在约90%以上,优选地约95%以上,更优选地约97%以上或约98%以上,更加优选地约99%以上,进一步更加优选地约99.5%以上(w/w)。
在本说明书中,“盐”意指医药、化妆品以及食品上可接受的且具有母体化合物(parent compound)的优选活性的根据本发明的一方面的盐。所述盐可以包含(1)由盐酸、氢溴酸、硫酸、硝酸、磷酸等之类无机酸形成;或由乙酸、丙酸、己酸、环戊烷丙酸、乙醇酸、丙酮酸、乳酸、丙二酸、琥珀酸、苹果酸、马来酸、富马酸、酒石酸、柠檬酸、苯甲酸、3-(4-羟基苯甲酰基)苯甲酸、肉桂酸、扁桃酸、甲烷磺酸、乙烷磺酸、1,2-乙烷-二磺酸、2-羟基乙烷磺酸、苯磺酸、4-氯苯磺酸、2-萘磺酸、4-甲苯磺酸、樟脑磺酸、4-甲基双环[2,2,2]-辛-2-烯-1-羧酸、葡庚糖酸、3-苯丙酸、三甲基乙酸、叔丁基乙酸、十二烷基硫酸、葡萄糖酸、谷氨酸、羟基萘甲酸、水杨酸、硬脂酸、粘康酸之类有机酸形成的酸加成盐(acid addition salt);或(2)母体化合物中存在的酸性质子被置换时形成的盐。另外,所述盐可以是药学上可接受的盐。
在本说明书中,“药学上可接受”意指以下可以得到政府或相当于政府的管制机构的认可或批准,或者被列入药典或被认知为其他一般药典:当以通常的医药服用量(medicinal dosage)利用时,避免显著的毒性效果,从而能够用于动物,更具体地用于人。
在本说明书中,“水合物(hydrate)”意指结合有水的化合物,并且是一个包含在水和化合物之间的不具有化学结合力的包合物的广义概念。
在本说明书中,“溶剂合物”意指在溶质的分子或离子与溶剂的分子或离子之间形成的高次化合物。
在本说明书中,“有效成分”意指能够单独示出所目标的活性或者与其本身没有活性的载体一起示出活性的成分。
在一实现例中,可以是,相对于组合物的总重量,所述麝香草酚三甲氧基肉桂酸酯、其立体异构体、盐、水合物或溶剂合物的含量为0.001重量%至20重量%。当所述麝香草酚三甲氧基肉桂酸酯、其立体异构体、盐、水合物或溶剂合物的含量为小于0.001重量%时,缓解皮肤瘙痒或刺激的效果降低,当超过20重量%时,剂型稳定性降低。具体地,所述麝香草酚三甲氧基肉桂酸酯、其立体异构体、盐、水合物或溶剂合物的含量为0.001重量%以上、0.002重量%以上、0.003重量%以上、0.004重量%以上、0.005重量%以上、0.01重量%以上、0.02重量%以上、0.03重量%以上、0.04重量%以上、0.05重量%以上、0.06重量%以上、0.07重量%以上、0.1重量%以上、0.2重量%以上、0.3重量%以上、0.4重量%以上、0.5重量%以上、0.6重量%以上、0.7重量%以上、1重量%以上、1.5重量%以上、2重量%以上、2.5重量%以上、3重量%以上、3.5重量%以上、4重量%以上、4.5重量%以上或5重量%以上的同时,20重量%以下、19.9重量%以下、19.8重量%以下、19.7重量%以下、19.6重量%以下、19.5重量%以下、19.4重量%以下、19.3重量%以下、19.2重量%以下、19.1重量%以下、19重量%以下、18.8重量%以下、18.6重量%以下、18.4重量%以下、18.2重量%以下、18重量%以下、17.8重量%以下、17.6重量%以下、17.4重量%以下、17.2重量%以下、17重量%以下、16.8重量%以下、16.6重量%以下、16.4重量%以下、16.2重量%以下、16重量%以下、15.5重量%以下、15重量%以下、14.5重量%以下、14重量%以下、13.5重量%以下、13重量%以下、12.5重量%以下、12重量%以下、11.5重量%以下、11重量%以下、10.5重量%以下或10重量%以下。
在一实现例中,基于所述组合物的投入的所述麝香草酚三甲氧基肉桂酸酯、其立体异构体、盐、水合物或溶剂合物可以以0.37至37mg/kg/日的给药量投入。当所述麝香草酚三甲氧基肉桂酸酯、其立体异构体、盐、水合物或溶剂合物的给药量小于0.37mg/kg/日时,皮肤瘙痒或刺激缓解效果降低,当超过37mg/kg/日时,能够刺激皮肤。具体地,基于所述组合物的投入的所述麝香草酚三甲氧基肉桂酸酯、其立体异构体、盐、水合物或溶剂合物的给药量可以是0.37mg/kg/日以上、0.38mg/kg/日以上、0.39mg/kg/日以上、0.4mg/kg/日以上、0.41mg/kg/日以上、0.42mg/kg/日以上、0.43mg/kg/日以上、0.44mg/kg/日以上、0.45mg/kg/日以上、0.5mg/kg/日以上、0.55mg/kg/日以上、0.6mg/kg/日以上、0.65mg/kg/日以上、0.7mg/kg/日以上、0.8mg/kg/日以上、0.9mg/kg/日以上、1mg/kg/日以上、1.1mg/kg/日以上、1.2mg/kg/日以上、1.3mg/kg/日以上、1.5mg/kg/日以上、1.7mg/kg/日以上、2mg/kg/日以上、3mg/kg/日以上、4mg/kg/日以上、5mg/kg/日以上、6mg/kg/日以上、7mg/kg/日以上、8mg/kg/日以上、9mg/kg/日以上、10mg/kg/日以上、11mg/kg/日以上、12mg/kg/日以上、13mg/kg/日以上、14mg/kg/日以上或15mg/kg/日以上的同时,37mg/kg/日以下、36.5mg/kg/日以下、36mg/kg/日以下、35.5mg/kg/日以下、35mg/kg/日以下、34.5mg/kg/日以下、34mg/kg/日以下、33.5mg/kg/日以下、33mg/kg/日以下、32.5mg/kg/日以下、32mg/kg/日以下、31.5mg/kg/日以下、31mg/kg/日以下、30.5mg/kg/日以下、30mg/kg/日以下、29.5mg/kg/日以下、29mg/kg/日以下、28.5mg/kg/日以下、28mg/kg/日以下、27.5mg/kg/日以下、27mg/kg/日以下、26.5mg/kg/日以下、26mg/kg/日以下、25.5mg/kg/日以下、25mg/kg/日以下、24.5mg/kg/日以下、24mg/kg/日以下、23.5mg/kg/日以下或23mg/kg/日以下。
在一实现例中,所述有效成分可以抑制电压门控钠通道NaV1.7(volt age-gatedsodium channel Nav1.7)。
在一实现例中,所述皮肤瘙痒或刺激可能是由于化学物质引起的。例如,所述化学物质可以是化学物质可以是藜芦碱(veratrum alkaloid),所述藜芦碱优选为藜芦定(veratridine)。
在一实现例中,所述组合物的给药途径不受限制,但优选地可以为经皮或者皮肤外用。
在一实现例中,所述组合物可以是化妆料组合物。所述化妆料组合物可以具有例如,柔软化妆水、收敛化妆水、营养化妆水、营养霜、按摩霜、眼霜、眼部精华、精华液、清洁霜、洁面乳、泡沫洗面奶、卸妆水、面膜、粉饼、身体乳、润肤霜、身体精华、沐浴乳、染发剂、洗发水、护发素、整发剂、养发剂、软膏、凝胶、面霜、贴剂、喷雾剂、粉末剂、以及皮肤粘合型等剂型,但不限于此。
另外,在各个剂型中,对于除了上述的必需成分之外的其它成分,本领域技术人员可以根据其它外用剂的种类或使用目的而无困难地合理选定并进行调配。
所述化妆料组合物可以以适合于局部适用的所有剂型提供。例如,可以以溶液、水相中分散油相而获得的乳液、油相中分散水相而获得的溶液、混悬液、固体、凝胶、粉末、糊剂、微针、泡沫(foam)或气溶胶组合物的剂型提供。这种剂型的组合物可以通过本技术领域的常规方法来制得。
在根据本说明书的化妆料组合物中,可以附加包含除了本说明书的化合物以外的功能性添加物以及包含在常规化妆料组合物中的成分。所述功能性添加物可以包含选自由水溶性维生素、油溶性维生素、高分子肽、高分子多糖、鞘脂以及海藻提取物组成的组中的成分。根据本说明书的化妆料组合物在不损害主功效的范围内可以优选地包含能够对主功效产生协同效应的其它成分。另外,根据本说明书的化妆料组合物可以进一步包含保湿剂、润滑剂、表面活性剂、紫外线吸收剂、防腐剂、杀菌剂、抗氧化剂、pH调节剂、有机以及无机颜料、香料、冷感剂或止汗剂。本领域技术人员可以在不损坏本说明书的目的以及效果的范围内容易地选定所述成分的调配量,可以是,以组合物总重量为基准,其调配量为0.001重量%至10重量%,具体为0.01重量%至3重量%。
在一实现例中,所述组合物可以是食品组合物。所述食品组合物的剂型不受特别限制,但可以配制成例如片剂、颗粒剂、丸剂、粉末剂、饮品剂之类液体制剂、焦糖、凝胶、棒、袋装茶等。对于各剂型的食品组合物,除了有效成分之外的通常使用的成分,本领域技术人员可以根据剂型或使用目的无困难地合理选定并进行调配,当与其它原料同时适用时,可能产生协同效应。
根据一实现例的食品组合物可以包含各种营养剂、维生素、矿物(电解质)、合成风味剂以及天然风味剂等风味剂、着色剂以及增进剂(芝士、巧克力等)、果胶酸及其盐、海藻酸及其盐、有机酸、保护性胶体增稠剂、pH调节剂、稳定剂、防腐剂,甘油、醇类、用于碳酸饮料的碳酸化剂等。另外,根据一实现例的食品组合物可以包含天然果汁以及用于制备果汁饮料和蔬菜饮料的果肉。这种成分可以单独或者组合使用。虽然这种添加剂的比率不是很重要,但一般来说,根据一实现例的组合物在每100重量份中包含0重量份至约50重量份的范围。
在一实现例中,所述组合物可以是药学组合物。所述药学组合物可以以口服、非口服、直肠、局部、经皮、静脉内、肌肉内、腹腔内、皮下等方式给药。用于口服给药的剂型可以是片剂、丸剂、软胶囊以及硬胶囊、颗粒剂、栓剂、细粒剂、液体制剂、乳浊剂或微丸剂,但不限于此。用于非口服给药的剂型可以是溶液剂、悬浮剂、乳剂、凝胶、注射剂、点滴剂、佐剂、贴剂或喷雾剂,但不限于此。所述剂型可以根据本技术领域的常规方法容易地制成,并且可以附加地包含表面活性剂、赋形剂、水合剂、乳化促进剂、悬浮剂、用于渗透压调节的盐或缓冲剂、着色剂、香辛料、稳定剂、防腐剂、保存剂或其它常用的辅助剂。
在另一方面,本公开提供包括向需要缓解皮肤瘙痒或皮肤刺激的个体中投入包含有效量的麝香草酚三甲氧基肉桂酸酯、其立体异构体、盐、水合物或溶剂合物的组合物的步骤的皮肤瘙痒或皮肤刺激缓解方法。在一观点上,所述方法的投入可以按照本说明书中记载的投入方法以及投入剂量来执行。
在另一方面,本公开提供用于制备皮肤瘙痒或皮肤刺激缓解用组合物的麝香草酚三甲氧基肉桂酸酯、其立体异构体、盐、水合物或溶剂合物的用途。
在又另一方面,本公开提供麝香草酚三甲氧基肉桂酸酯、其立体异构体、盐、水合物或溶剂合物的皮肤瘙痒或皮肤刺激缓解用途。
以下,将通过实施例等更详细地说明本发明。这些实施例仅仅是用于例示本发明,对于本技术领域中具有通常知识的人来说显而易见的是,本发明的范围不应被解释为受这些实施例的限制。
[实施例1]麝香草酚三甲氧基肉桂酸酯
从COSMANN公司(位于韩国京畿道华城市)获得CAS编号504394-57-4的麝香草酚三甲氧基肉桂酸酯。
[实验例1]评估电压门控钠通道NaV1.7的抑制效果
为了按照如下那样评估麝香草酚三甲氧基肉桂酸酯的电压门控钠通道NaV1.7(voltage-gated sodium channel Nav1.7)抑制效果,利用了人Nav1.7–HEK293细胞系(密理博(Millipore)公司)。人Nav1.7–HEK293细胞系是在HEK293(人胚胎肾细胞293;humanembryonic kidney 293)细胞中将人Nav1.7基因转染而稳定化的细胞系。实验前一天,将人Nav1.7-HEK293细胞在96孔板中以8x104细胞数/孔分装后,在37℃、5%CO2培养箱中培养24小时。培养时的培养基使用了含10%的牛血清(Fetal bovine serum,FBS)的DMEM/F12培养基,并添加了遗传霉素(Geneticin,赛默飞世尔科技(Thermo FisherScientific)公司)以保持稳定的细胞。
24小时之后,使用20mM HEPES Hanks平衡盐溶液(Hanks’Balanced Saltsolution;HBSS)缓冲液(以下,反应缓冲液,赛默飞世尔科技(ThermoFisher Scientific)公司)清洗1次96孔板后,将膜电位荧光染料(membranepotential fluorescence dye,美国分子仪器(Molecular Devices)公司)添加到人Nav1.7-HEK293细胞中。在37℃、5%CO2培养箱中反应40分钟后,在人Nav1.7-HEK293细胞上处理实施例1的麝香草酚三甲氧基肉桂酸酯。反应10分钟之后,利用荧光读板机即FlexStation3(美国分子仪器(Molecular Device)公司)对每孔测定55秒内处理刺激原因30microM藜芦定(veratridine)时变化的膜电位变化。
分别求出经过实施例1、反应缓冲液、藜芦定处理后,测定55秒内荧光(fluorescence)的变化而获得的值的初始值与最大值之差。将在藜芦定处理中仅处理反应缓冲液时的值的差与在实施例1处理中仅处理反应缓冲液时的值进行比较并求出抑制率。与其相同的方法求出用作局部麻醉剂的同时瘙痒缓解剂的利多卡因(lidocaine,希格玛(Sigma)公司)的抑制率之后,与实施例1进行比较,其结果在下述表1以及图1中示出。
[表1]
实施例1 | 利多卡因 | |
IC50(μM) | 3.1 | 28.7 |
其结果,可以确认实施例1的麝香草酚三甲氧基肉桂酸酯以浓度依赖性的方式抑制电压门控钠通道NaV1.7而能够缓解皮肤瘙痒和皮肤刺激。另外,可以确认与相同浓度的利多卡因相比,实施例1的电压门控钠通道NaV1.7抑制效果优异。
[实验例2]膜片钳评估(基于Nav1.7人钠离子通道细胞的全自动膜片钳分析)
使用基于Nav1.7人钠离子通道细胞的全自动膜片钳分析(Nav1.7Human SodiumIon Channel Cell Based Automated Patch Clamp Assay)(欧陆集团(Eurofins),CYL8011QP2)执行膜片钳评估。在控制步骤中,将超过200pA的电流振幅进行了分析。电流的振幅是将进入-10mV(即,电流的峰值)步骤时峰值内部电流和步骤末端上残留的电流之差进行测定并计算。电流在空白对照(vehicle control)条件下被评估后,适用各化学物5分钟后被评估。
钠通道a)在-120mV中以停用或闭合状态,c)在0mV中以非激活状态,b)在非激活的临时开放状态存在。在0mV中通过测定1~2ms内的钠电流来测定开放通道抑制(脉冲1)。为了使钠通道完全激活并促进药物的非激活状态依赖性结合,将通道从开放状态(0mV)保持更长,在10ms内再次阶段性地回到-120mV而在非激活状态下恢复为停用或闭合状态。而且,为了测定可以打开的钠通道,在50ms内阶段性地进入0mV,评估非激活状态的抑制(脉冲2)。各浓度化合物适用了5分钟,其结果在下述表2中示出。
[表2]
由所述表2的结果能够确认,实施例1根据浓度,在脉冲1和脉冲2中全部显示抑制效果。
[实验例3]瘙痒缓解临床功效评估
以平时皮肤干燥、过敏性皮肤炎、敏感性皮肤等原因长期感觉到瘙痒的受试者为对象进行了瘙痒缓解功效评估。当瘙痒发生30分钟以上时,涂上含有0.5%浓度的实施例1的乳液,利用以涂布前和涂布后的瘙痒程度为评分标准的数字评定量表(NumericalRating Scale)进行评估。当以瘙痒程度从0(无瘙痒)到10(可想象的最严重的瘙痒)为尺度,不同受试者发生瘙痒情况时,经过2分钟、10分钟、30分钟的评估,将其结果在图2(**p<0.01,***p<0.001)中示出。含有所述实施例1的乳液的组分如下述表3所示。
[表3]
成分 | 含量(重量%) |
甘油硬脂酸酯柠檬酸酯 | 1.5 |
C12-15烷基苯甲酸酯、C12-15醇 | 7.5 |
辛基十二醇 | 3.0 |
鲸蜡硬脂醇 | 1.0 |
实施例1 | 0.5 |
氨丁三醇 | 0.1 |
卡波姆 | 0.15 |
乙基己基甘油 | 0.05 |
甘油辛酸酯 | 0.1 |
己二醇 | 0.9 |
净化水 | 余量 |
合计 | 100.0 |
如图2所示,将含有实施例1的乳液的涂布前和涂布后的同一时间进行成对比较,可知在所有时间都显著地抑制瘙痒。
[剂型例1]化妆水
按照下述表4中记载的组分,通过常规的方法制备化妆水。
[表4]
成分 | 含量(重量%) |
麝香草酚三甲氧基肉桂酸酯 | 0.1 |
甘油 | 3.0 |
丁二醇 | 2.0 |
丙二醇 | 2.0 |
羧乙烯基聚合物 | 0.1 |
PEG 12任烷基酚聚乙二醇醚 | 0.2 |
聚山梨酯80 | 0.4 |
乙醇 | 10.0 |
pH调节剂 | 0.1 |
防腐剂、色素、香料 | 0.1 |
净化水 | 余量 |
合计 | 100 |
[剂型例2]面霜
按照下述表5中记载的组分,通过常规的方法制备面霜。
[表5]
成分 | 含量(重量%) |
麝香草酚三甲氧基肉桂酸酯 | 1 |
聚山梨酯80 | 1.5 |
山梨坦倍半油酸酯 | 0.5 |
PEG 60氢化蓖麻油 | 2.0 |
液体石蜡 | 10.0 |
角鲨烷 | 5.0 |
辛酸/癸酸甘油三酯 | 5.0 |
甘油 | 5 |
丁二醇 | 3.0 |
丙二醇 | 3.0 |
pH调节剂 | 0.2 |
防腐剂、色素、香料 | 0.1 |
净化水 | 余量 |
合计 | 100 |
[剂型例3]乳液
按照下述表6中记载的组分,通过常规的方法制备乳液。
[表6]
成分 | 含量(重量%) |
甘油硬脂酸酯柠檬酸酯 | 1.5 |
C12-15烷基苯甲酸酯、C12-15醇 | 7.5 |
辛基十二醇 | 3.0 |
鲸蜡硬脂醇 | 1.0 |
麝香草酚三甲氧基肉桂酸酯 | 0.5 |
氨丁三醇 | 0.1 |
卡波姆 | 0.15 |
乙基己基甘油 | 0.05 |
甘油辛酸酯 | 0.1 |
己二醇 | 0.9 |
净化水 | 余量 |
合计 | 100.0 |
[剂型例4]按摩霜
按照下述表7中记载的组分,通过常规的方法制备按摩霜。
[表7]
成分 | 含量(重量%) |
麝香草酚三甲氧基肉桂酸酯 | 0.5 |
蜜蜡 | 10.0 |
聚山梨酯80 | 1.5 |
PEG 60氢化蓖麻油 | 2.0 |
山梨坦倍半油酸酯 | 0.8 |
液体石蜡 | 40 |
角鲨烷 | 5.0 |
辛酸/癸酸甘油三酯 | 4.0 |
甘油 | 5.0 |
丁二醇 | 3.0 |
丙二醇 | 3.0 |
pH调节剂 | 0.2 |
防腐剂、色素、香料 | 0.1 |
净化水 | 余量 |
合计 | 100 |
[剂型例5]面膜
按照下述表8中记载的组分,通过常规的方法制备面膜。
[表8]
成分 | 含量(重量%) |
麝香草酚三甲氧基肉桂酸酯 | 1 |
聚乙烯醇 | 13.0 |
羧甲基纤维素钠 | 0.2 |
甘油 | 5.0 |
尿囊素 | 0.1 |
乙醇 | 6.0 |
PEG12任烷基酚聚乙二醇醚 | 0.3 |
聚山梨酯60 | 0.3 |
防腐剂、色素、香料 | 0.1 |
净化水 | 余量 |
合计 | 100 |
[剂型例6]凝胶
按照下述表9中记载的组分,通过常规的方法制备凝胶。
[表9]
成分 | 含量(重量%) |
麝香草酚三甲氧基肉桂酸酯 | 0.5 |
聚乙烯醇 | 13.0 |
羧甲基纤维素钠 | 0.2 |
甘油 | 5.0 |
尿囊素 | 0.1 |
乙醇 | 6.0 |
PEG12任烷基酚聚乙二醇醚 | 0.3 |
聚山梨酯60 | 0.3 |
防腐剂、色素、香料 | 0.1 |
净化水 | 余量 |
合计 | 100 |
[剂型例7]软膏
按照下述表10中记载的组分,通过常规的方法制备软膏。
[表10]
[剂型例8]洗发水
按照下述表9中记载的组分,通过常规的方法制备洗发水。
[表11]
成分 | 含量(重量%) |
麝香草酚三甲氧基肉桂酸酯 | 1 |
液体石蜡 | 7.0 |
鲸蜡硬脂基葡糖苷 | 1.5 |
山梨坦硬脂酸酯 | 0.4 |
角鲨烷 | 5.0 |
辛酸/癸酸甘油三酯 | 3.0 |
聚山梨酯 | 1.2 |
卡波姆 | 0.1 |
甘油 | 3.0 |
丁二醇 | 3.0 |
pH调节剂 | 0.2 |
防腐剂、色素、香料 | 0.1 |
净化水 | 余量 |
合计 | 100 |
[剂型例9]软胶囊
将100mg的麝香草酚三甲氧基肉桂酸酯、160mg的左旋肉碱、320mg的大豆油、2mg的棕榈油、8mg的植物性硬化油、4mg的黄蜡以及6mg的卵磷脂混合,按照常规方法装入1粒胶囊中,制成软胶囊。
[剂型例10]片剂
将120mg的麝香草酚三甲氧基肉桂酸酯、500mg的低聚半乳糖、80mg的乳糖以及220mg的麦芽糖混合,利用流化床干燥器造粒后,添加6mg的糖酯(sugar ester),用压片机进行压制制成片剂。
[剂型例11]颗粒剂
将100mg的麝香草酚三甲氧基肉桂酸酯、250mg的无水结晶葡萄糖以及550mg淀粉混合,使用流化床造粒机成型为颗粒后,装入袋中,制成颗粒剂。
[剂型例12]饮品剂
将120mg的麝香草酚三甲氧基肉桂酸酯、10g的葡萄糖、0.6g的枸橼酸、以及25g的液态低聚糖混合后,加入500ml的净化水,每瓶中装入200ml。装入瓶中之后,在130℃下杀菌4~5秒,制成饮品。
本说明书通过不限制权利要求书的下述实现例来附加说明。
实现例1:用于制备皮肤瘙痒或刺激缓解用组合物的麝香草酚三甲氧基肉桂酸酯、其立体异构体、盐、水合物或溶剂合物的用途。
实现例2:作为实现例1的用途,所述麝香草酚三甲氧基肉桂酸酯由下述化学式1表示。
[化学式1]
实现例3:作为实现例1或实现例2的用途,所述麝香草酚三甲氧基肉桂酸酯、其立体异构体、盐、水合物或溶剂合物的给药量为0.37至37mg/kg/日。
实现例4:作为实现例1至实现例3中的任一用途,相对于组合物总重量,所述麝香草酚三甲氧基肉桂酸酯、其立体异构体、盐、水合物或溶剂合物的含量为0.001至20重量%。
实现例5:实现例1至实现例4中的任一用途,所述组合物抑制电压门控钠通道NaV1.7。
实现例6:作为实现例1至实现例5中的任一用途,所述皮肤瘙痒或皮肤刺激由化学物质引起的。
实现例7:作为实现例1至实现例6中的任一用途,所述组合物为皮肤外用剂组合物。
实现例8:作为实现例1至实现例7中的任一用途,所述组合物为食品组合物。
实现例9:实现例1至实施例中的任一用途,所述组合物为化妆料组合物。
实现例10:作为实现例1至实施例9中的任一用途,所述组合物为药学组合物。
Claims (10)
1.一种麝香草酚三甲氧基肉桂酸酯、其立体异构体、盐、水合物或溶剂合物的用途,用于制备皮肤瘙痒或皮肤刺激缓解用组合物。
3.根据权利要求1所述的用途,其中,
所述麝香草酚三甲氧基肉桂酸酯、其立体异构体、盐、水合物或溶剂合物的给药量为0.37至37mg/kg/日。
4.根据权利要求1所述的用途,其中,
相对于组合物总重量,所述麝香草酚三甲氧基肉桂酸酯、其立体异构体、盐、水合物或溶剂合物的含量为0.001至20重量%。
5.根据权利要求1所述的用途,其中,
所述组合物抑制电压门控钠通道NaV1.7。
6.根据权利要求1所述的用途,其中,
所述皮肤瘙痒或皮肤刺激是由化学物质引起的。
7.根据权利要求1至6中任一项所述的用途,其中,
所述组合物为皮肤外用剂组合物。
8.根据权利要求1至6中任一项所述的用途,其中,
所述组合物为食品组合物。
9.根据权利要求1至6中任一项所述的用途,其中,
所述组合物为化妆料组合物。
10.根据权利要求1至6中任一项所述的用途,其中,
所述组合物为药学组合物。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2020-0096647 | 2020-08-03 | ||
KR1020200096647A KR20220017018A (ko) | 2020-08-03 | 2020-08-03 | 티몰 트리메톡시신나메이트를 포함하는 피부 가려움 또는 자극 완화용 조성물 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN114053259A true CN114053259A (zh) | 2022-02-18 |
Family
ID=80002435
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110884099.6A Pending CN114053259A (zh) | 2020-08-03 | 2021-08-03 | 包含麝香草酚三甲氧基肉桂酸酯的皮肤瘙痒或刺激缓解用组合物 |
Country Status (4)
Country | Link |
---|---|
US (1) | US11583512B2 (zh) |
JP (1) | JP2022028622A (zh) |
KR (1) | KR20220017018A (zh) |
CN (1) | CN114053259A (zh) |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0029100D0 (en) | 2000-11-29 | 2001-01-10 | Karobio Ab | Compounds active at the glucocorticoid receptor |
JP2002284705A (ja) | 2001-01-19 | 2002-10-03 | Shiseido Co Ltd | 刺激緩和剤 |
KR100457949B1 (ko) | 2001-09-24 | 2004-11-18 | 주식회사 태평양 | 3,4,5-트리메톡시 페닐아세트산, 3,4,5-트리메톡시 신남산또는 3,4,5-트리메톡시 히드로 신남산의 에스테르화합물 및 이를 함유하는 미백 화장료조성물 |
GB2471135A (en) | 2009-06-19 | 2010-12-22 | H D S Ltd | Hair dye composition and use in reducing contact allergy |
FR3000742B1 (fr) | 2013-01-08 | 2015-08-21 | Pharmasynthese | Nouveaux derives de l’acide sinapinique |
KR20180017459A (ko) | 2016-08-09 | 2018-02-21 | 주식회사 엘지생활건강 | 항산화 화장료 조성물 |
KR102068635B1 (ko) | 2016-10-26 | 2020-01-21 | (주)아모레퍼시픽 | 3,4,5-트리메톡시 신남산 에스테르 유도체와 그 제조방법 및 이를 포함하는 피부 미백용 조성물 |
-
2020
- 2020-08-03 KR KR1020200096647A patent/KR20220017018A/ko active Search and Examination
-
2021
- 2021-07-26 JP JP2021121587A patent/JP2022028622A/ja active Pending
- 2021-07-29 US US17/388,581 patent/US11583512B2/en active Active
- 2021-08-03 CN CN202110884099.6A patent/CN114053259A/zh active Pending
Also Published As
Publication number | Publication date |
---|---|
US20220031648A1 (en) | 2022-02-03 |
JP2022028622A (ja) | 2022-02-16 |
US11583512B2 (en) | 2023-02-21 |
KR20220017018A (ko) | 2022-02-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR102092849B1 (ko) | 피부 미백용 조성물 | |
KR20200015443A (ko) | 항알레르기성 미용 조성물 | |
CN107412031B (zh) | 含有橘皮素的皮肤外用剂组合物 | |
KR101510595B1 (ko) | 유제놀을 유효성분으로 함유하는 아토피성 피부염의 예방 또는 치료용 조성물 | |
KR100846125B1 (ko) | 피페린을 유효성분으로 포함하는 피부주름 개선용 조성물 | |
US20180078482A1 (en) | Composition containing theasapogenol derivative as active ingredient | |
KR102645439B1 (ko) | 아우레오바시디움 풀루란스 균주의 배양물 또는 추출물을 포함하는 저자극 피부 재생 또는 피부 진정용 조성물 | |
CN110913833B (zh) | 包含槲皮素类化合物的美白组合物 | |
CN110022848B (zh) | 包含胡椒素的抗应激组合物 | |
CN114053259A (zh) | 包含麝香草酚三甲氧基肉桂酸酯的皮肤瘙痒或刺激缓解用组合物 | |
KR101665381B1 (ko) | 록삼피어 추출물을 함유하는 피부외용제 조성물 | |
KR20160058739A (ko) | 폴리페놀 화합물을 함유하는 모공 축소용 조성물 | |
KR102105533B1 (ko) | 아마이드 유도체 화합물 | |
KR102039608B1 (ko) | 미도드린을 포함하는 조성물 및 이의 용도 | |
KR101906896B1 (ko) | 티몰 및 미르센을 유효성분으로 함유하는 아토피성 피부염의 예방 또는 치료용 조성물 | |
KR102672903B1 (ko) | 테아시넨신 a를 포함하는 화장료 조성물 | |
CN111100179A (zh) | 获得化合物的方法 | |
US20200115409A1 (en) | Anti-inflammatory composition including novel kaempferol-based compound derived from post-fermented tea | |
CN112912057B (zh) | 含有聚酯型儿茶素a的化妆料组合物 | |
KR101965590B1 (ko) | Abh 항원의 발현을 조절하는 물질을 포함하는 피부 미백용 조성물 | |
US20220241168A1 (en) | Composition for stimulating beta-endorphin production comprising sanshool | |
US20230363997A1 (en) | Composition for suppressing skin irritation or inhibiting sebum secretion | |
KR20180034126A (ko) | 마그놀롤을 포함하는 항스트레스 조성물 | |
KR20180010084A (ko) | 3-O-갈로일-3,3',5,5',7-펜타하이드록시플라반(3-O-galloyl-3,3',5,5',7- pentahydroxyflavan)을 포함하는 보습용 조성물 | |
KR20210121894A (ko) | 글리시쿠마린을 포함하는 피부장벽기능 손상 완화용 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |